Fibrin-targeting PLGA microspheres for prevention of post-operative peritoneal adhesions; a pre-clinical proof of concept study

纤维蛋白靶向 PLGA 微球用于预防术后腹膜粘连;

基本信息

  • 批准号:
    MR/W019310/1
  • 负责人:
  • 金额:
    $ 68.58万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    未结题

项目摘要

After abdominal surgery, an unwanted scar tissue is frequently formed, binding the abdominal organs together. This is called a post-operative adhesion, which occurs in most patients. The adhesion is often so excessive or persistent that it can cause a range of complications, including pain, discomfort and more seriously bowel obstruction and female infertility. The only effective therapy of post-surgical adhesions, once developed, is corrective surgery. The cost for treating post-surgical adhesion-related problems is extremely expensive, calculated to be >£50 million/year in the UK. Therefore, prevention of post-surgical adhesions is of great value. To date, no effective drug has been successfully developed for this purpose. Instead, an increasing number of biomaterial products, including artificial films and gels, have been produced for use in hospitals. These products can separate the damaged tissues from surrounding tissues, limiting the adhesion formation. Having said this, these products are only effective in half of the patients treated. Therefore, there is a great unmet need for a more effective treatment to prevent post-operative adhesion formation. Based on our recent scientific discovery, we propose a new technology to prevent post-operative adhesions using micrometre-sized man-made spheres, which are designed to gather at the damaged tissue surface and prevent adhesion formation. We will use a biomaterial that has proven safe to use in the patients. This advanced technology has a range of significant advantages over the current preventative methods, in terms of greater effectiveness, higher specificity, and less complications. Indeed, our pilot study suggested that this technology reduced adhesions after abdominal operation without any adverse event. Thus, the primary aim of this project is to establish robust pre-clinical evidence for the safety and usefulness of this promising treatment to prevent post-operative adhesion formation. We will optimize the particle size, design, and dose, and confirm its safety and effectiveness in multiple clinically relevant models of post-operative adhesions. We will also systematically explore the biological insights relevant to the safety and benefits of this treatment. The results obtained will validate the progression of this cutting-edge advanced technology to the next stage of development toward early clinical adoption. In addition, this project will provide important, previously unknown scientific knowledge to understand the formation of post-operative adhesions, macrophage biology, and biomaterial and engineering technology. These will shed light on the new scientific perceptions, which will pave the way to future medical and scientific research. Therefore, this project has great potential to benefit the scientists, patients, doctors, the NHS, and society. There are also commercial opportunities associated with this innovative technology for post-operative adhesion as the relevant market is huge.
腹部手术后,经常会形成多余的疤痕组织,将腹部器官捆绑在一起。这被称为术后粘连,大多数患者都会发生这种情况。粘连往往过多或持续,会导致一系列并发症,包括疼痛、不适,更严重的是肠梗阻和女性不孕。手术后粘连的唯一有效治疗方法,一旦开发出来,就是矫正手术。治疗手术后粘连相关问题的费用极其昂贵,在英国,计算起来是5000万英镑/年。因此,预防术后粘连具有重要价值。到目前为止,还没有成功地开发出用于这一目的的有效药物。取而代之的是,越来越多的生物材料产品被生产出来,包括人造薄膜和凝胶,用于医院。这些产品可以将受损组织与周围组织分开,限制粘连的形成。话虽如此,这些产品只对一半接受治疗的患者有效。因此,需要一种更有效的治疗方法来防止术后粘连的形成,这是一个尚未得到满足的需求。根据我们最近的科学发现,我们提出了一种新的技术来防止术后粘连,使用微米大小的人造球体,旨在聚集在受损的组织表面,防止粘连形成。我们将使用一种已被证明在患者身上安全使用的生物材料。与当前的预防方法相比,这项先进的技术具有一系列显著的优势,包括更有效、更高的特异性和更少的并发症。事实上,我们的初步研究表明,这项技术减少了腹部手术后的粘连,没有任何不良事件。因此,这个项目的主要目的是建立强有力的临床前证据,证明这种有希望的治疗方法的安全性和有效性,以防止术后粘连形成。我们将优化颗粒大小、设计和剂量,并在多种临床相关的术后粘连模型中证实其安全性和有效性。我们还将系统地探索与这种治疗的安全性和益处相关的生物学见解。所获得的结果将验证这一尖端先进技术进入早期临床采用的下一阶段开发的进展。此外,该项目将提供重要的、以前未知的科学知识,以了解术后粘连的形成、巨噬细胞生物学以及生物材料和工程技术。这些将阐明新的科学观念,为未来的医学和科学研究铺平道路。因此,该项目具有巨大的潜力,将造福于科学家、患者、医生、NHS和社会。这种用于术后粘连的创新技术也有商业机会,因为相关市场巨大。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ken Suzuki其他文献

Determination of N* amplitudes from associated strangeness production in p+p collisions
根据 p p 碰撞中相关奇异值的产生确定 N* 振幅
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    R. Munzer;L. Fabbietti;E. Epple;S. Lu;P. Klose;F. Hauenstein;N. Herrmann;D. Grzonka;D. Grzonka;Y. Leifels;M. Maggiora;D. Pleiner;B. Ramstein;J. Ritman;J. Ritman;E. Roderburg;P. Salabura;A. Sarantsev;Z. Basrak;P. Buehler;M. Cargnelli;R. Čaplar;H. Clement;O. Czerwiakowa;I. Deppner;M. Dželalija;W. Eyrich;Z. Fodor;P. Gasik;I. Gašparić;A. Gillitzer;A. Gillitzer;Y. Grishkin;O. Hartmann;K. Hildenbrand;B. Hong;T. I. Kang;J. Kecskeméti;Yongsu Kim;M. Kirejczyk;M. Kis;P. Koczoń;R. Kotte;A. Lebedev;A. Fèvre;J. Liu;V. Manko;J. Marton;T. Matulewicz;K. Piasecki;F. Rami;A. Reischl;Ryu;P. Schmidt;Z. Seres;B. Sikora;K. Sim;K. Siwek;V. Smolyankin;Ken Suzuki;Z. Tymiński;P. Wagner;I. Weber;E. Widmann;K. Wisniewski;Z. Xiao;T. Yamasaki;I. Yushmanov;P. Wintz;Y. Zhang;A. Zhilin;V. Zinyuk;J. Zmeskal
  • 通讯作者:
    J. Zmeskal
Genotype-phenotype and structure-phenotype correlations of the insulin receptor gene mutations in patients with severe insulin resistance.
严重胰岛素抵抗患者胰岛素受体基因突变的基因型-表型和结构-表型相关性。
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jun Hosoe;Hiroko Kadowaki;Fuyuki Miya;Minaka Takakura;Katsuya Aizu;Ichiro Miyata;Tomoyuki Kawamura;Kenichi Satomura;Takeru Ito;Kazuo Hara;Masaki Tanaka;Hiroyuki Ishiura;Shoji Tsuji;Ken Suzuki;Tatsuhiko Tsunoda;Nobuhiro Shojima;Toshimasa Ya
  • 通讯作者:
    Toshimasa Ya
日本の都道府県における議案形成過程の集権化と執政-議会関係
日本都道府县的法案制定过程和行政议会关系的集中化
  • DOI:
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tatsuhiko Naito;Wataru Satake;Kotaro Ogawa;Ken Suzuki;Jun Hirata;Jia Nee Foo;Eng-King Tan;Tatsushi Toda;Yukinori Okada;竹中勇貴
  • 通讯作者:
    竹中勇貴
Measurement of the local residual stress between fine metallic bumps in 3D flip chip structures
测量 3D 倒装芯片结构中精细金属凸块之间的局部残余应力
1 1 Reparative macrophages regulate fibrosis by attenuating apoptosis and 2 senescence of fibroblasts 3 4 5 6
1 1 修复性巨噬细胞通过减少细胞凋亡和 2 成纤维细胞衰老来调节纤维化 3 4 5 6
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Shiraishi;A. Yamaguchi;Ken Suzuki
  • 通讯作者:
    Ken Suzuki

Ken Suzuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ken Suzuki', 18)}}的其他基金

Facilitation of collaboration with Professor N Rosenthal: Study of the role of IGF-1 in cell therapy for heart failure
促进与 N Rosenthal 教授的合作:研究 IGF-1 在心力衰竭细胞治疗中的作用
  • 批准号:
    G0600872/1
  • 财政年份:
    2007
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Research Grant
Role of Cell Transplantation in Treating Heart Failure
细胞移植在治疗心力衰竭中的作用
  • 批准号:
    G116/158/2
  • 财政年份:
    2007
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Fellowship
Facilitation of collaboration with Professor N Rosenthal: Study of the role of IGF-1 in cell therapy for heart failure
促进与 N Rosenthal 教授的合作:研究 IGF-1 在心力衰竭细胞治疗中的作用
  • 批准号:
    G0600872/2
  • 财政年份:
    2007
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Research Grant

相似国自然基金

靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
  • 批准号:
    82373145
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
诱导性多能干细胞rDNA区基因打靶在线粒体视神经病中的治疗研究
  • 批准号:
    81970829
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
Pre-targeting/Click反应介导的自体循环干细胞在心脏缺血损伤修复中的应用及机制研究
  • 批准号:
    81873493
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
以IGF2/IGF1R与SYT/SSX1为靶点治疗滑膜肉瘤的实验研究
  • 批准号:
    81102033
  • 批准年份:
    2011
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
基于ZFN/phiC31系统的新型基因打靶技术的建立(果蝇)
  • 批准号:
    31171278
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Fragment to small molecule hit discovery targeting Mycobacterium tuberculosis FtsZ
针对结核分枝杆菌 FtsZ 的小分子片段发现
  • 批准号:
    MR/Z503757/1
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Research Grant
Targeting metabolism to improve the host response to peritoneal dialysis
靶向代谢以改善宿主对腹膜透析的反应
  • 批准号:
    MR/Y013816/1
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Research Grant
Targeting Inhibitory kappa B kinase alpha (IKKalpha): a new treatment paradigm for inflammatory-driven cancers
靶向抑制性 kappa B 激酶 alpha (IKKalpha):炎症驱动的癌症的新治疗范例
  • 批准号:
    MR/Y015479/1
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Research Grant
Development of a novel cancer immunotherapy model targeting human macrophages
开发针对人类巨噬细胞的新型癌症免疫治疗模型
  • 批准号:
    24K18516
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Designing Rational Combinations to Improve CAR T Cell Therapy for Prostate Cancer
设计合理的组合以改善前列腺癌的 CAR T 细胞疗法
  • 批准号:
    10752046
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
  • 批准号:
    10991546
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
Genetic targeting of a synthetic dye for voltage imaging of cerebellar Purkinje neurons during a tongue grasping task
一种合成染料的基因靶向,用于抓取舌头任务期间小脑浦肯野神经元的电压成像
  • 批准号:
    23K27147
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Cell-penetrating monobodies targeting oncogenic KRAS
SBIR 第一阶段:针对致癌 KRAS 的细胞穿透单体
  • 批准号:
    2321926
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Standard Grant
Targeting soluble guanylate cyclase as a novel strategy to treat and prevent cardiac arrhythmias: efficacy and mechanisms
靶向可溶性鸟苷酸环化酶作为治疗和预防心律失常的新策略:功效和机制
  • 批准号:
    MR/Y003594/1
  • 财政年份:
    2024
  • 资助金额:
    $ 68.58万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了